Cilostazol patient counseling information

Cilostazol
PLETAL® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Studies
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Information for Patients

• Please refer to the patient package insert.
• Patients should be advised to read the patient package insert for PLETAL carefully before starting therapy and to reread it each time therapy is renewed in case the information has changed.
• Patients should be advised to take PLETAL at least one-half hour before or two hours after food.

• Patients should be advisedthat the beneficial effects of PLETAL on the symptoms of intermittent claudication may not be immediate. Although the patient may experience benefit in 2 to 4 weeks after initiation of therapy, treatment for up to 12 weeks may be required before a beneficial effect is experienced.

References

Adapted from the FDA Package Insert.